SAN FRANCISCO, Jan 13 (Reuters) - AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use of artificial intelligence to accelerate the discovery of new drugs.
The companies did not disclose financial terms. In a press release, Modella AI said its "foundation models" and AI agents would be integrated into oncology research and development to support clinical development and biomarker discovery.
"Oncology drug development is becoming more complex, more data-rich and more time-sensitive," said Gabi Raia, Modella AI's chief commercial officer, adding that joining AstraZeneca would allow it to deploy its tools in global trials and clinical settings.
AstraZeneca said that this was the first acquisition of an AI firm by a big pharmaceutical company.
In an interview at the JP Morgan Healthcare Conference, AstraZeneca Chief Financial Officer Aradhana Sarin said the acquisition would "supercharge" the company's quantitative pathology and biomarker discovery efforts by bringing more data and AI capabilities in-house.
The deal was one of a number of pacts between major drug firms and AI companies that were unveiled at the healthcare conference, including a $1 billion collaboration between Nvidia and Eli Lilly. They plan to build a new research lab using Nvidia's latest-generation AI chips.
Modella will accelerate AstraZeneca’s efforts to make pathology more quantitative - using computers to analyze biopsies for relevant proteins and correlate them with clinical data - so AstraZeneca can develop “highly targeted biomarkers and then highly targeted therapeutics,” Sarin said.
The deal is an expansion of a multi-year collaboration that the companies unveiled in July.
Sarin said that partnership served as a "test drive," adding that AstraZeneca ultimately wanted Modella's data, foundation models and AI talent in-house.
She said AI tools could be used to more rapidly select patients for drug trials, which could increase the odds of clinical success and cut related costs.
(Reporting by Maggie Fick; Editing by Thomas Derpinghaus)
LATEST POSTS
- 1
The Response to Independence from the rat race: Methodologies for Creating Financial momentum - 2NASA will bring space station crew home early after medical issue
- 3An Artemis 2 astronaut took a 'bath' on camera on the way to the moon. Mission Control's reaction was priceless (video)
- 4How to watch ‘The Traitors’ U.K. Season 4 from the U.S.
- 5Netanyahu on Gush Etzion terror attack: 'We will complete war on all fronts'
- Outside Lovers' Decision: Favored Climbing Rucksacks
- Empathy and reasoning aren’t rivals – new research shows they work together to drive people to help more
- Europe: 4 Urban communities for a Paramount Social Experience
- IDF bans Android phones for senior officers, iPhones now mandatory, Army Radio reports
- Instructions to Perceive and Grasp the Early Side effects of Cellular breakdown in the lungs
- Woman charged in unprovoked stabbing of tourist changing baby's diaper in Macy’s Herald Square store
- Airbnb Unveils Airport Pickup Service Across 125 Cities in Global Expansion
- Conquering Language Boundaries: Individual Accounts of Multilingualism
- Chinese construction workers in Israel: 'I’d rather be bombed than live in poverty'
